Insights - Selecta provided an update this morning for their dose escalating trial for the co-administration of: 1. 0.125mg/kg of SVP-rapamycin + 0.4mg/kg of pegsiticase 2. 0.15 … Continue Reading
Read NowInsights - SWK Holdings (SWKH) announced Q4 and full year 2017 earnings earlier this week and the company is continuing to execute on their business. We initially discussed SWK … Continue Reading
Premium: Read NowInsights - Selecta held a conference call to discuss their Q4 2017 results and provided a corporate update. Overall, we believe the call was positive and shed light … Continue Reading
Premium: Read NowInsights - On March 20th, 2018 SlingShot Insights hosted a KOL call with Dr. Dr Gail Kerr – MD, discussing Selecta (SELB) candidate SEL-212 and Krystexxa, the … Continue Reading
Premium: Read NowInsights - This morning, Fennec (FENC) announced that the FDA had granted the company’s candidate, Pedmark, Breakthrough Therapy Designation for the prevention of cisplatin-related ototoxicity in pediatric patients with … Continue Reading
Read NowInsights - On Thursday, March 8th, 2018 SlingShot Insights hosted a KOL call with Dr.Vibeke Strand, discussing Selecta (SELB) and the current treatments for gout. Below are … Continue Reading
Premium: Read NowInsights - After market close on Thursday, Global Blood Therapeutics (GBT) announced an offering of 4M shares with a 30-day option to purchase additional 600,000 shares at $54/share. This … Continue Reading
Premium: Read Now
